Shanghai Vitalgen BioPharma Co., Ltd, a biopharmaceutical company based in China, has initiated a Phase I/II clinical study for its gene therapy candidate VGN-R09b at Huashan Hospital, targeting primary Parkinson’s disease (PD). VGN-R09b received clearance to proceed with clinical trials in China for primary PD and aromatic L-amino acid decarboxylase deficiency (AADCD) in April this year. A pivotal trial for AADCD was launched in Shanghai earlier this month.
The company’s proprietary gene therapy employs recombinant adeno-associated virus (rAAV) as a vector to deliver functional AADCs, aiming to restore dopamine production and consequently provide therapeutic benefits for PD patients. By injecting VGN-R09b directly into the striatum, a region of the brain affected by PD, it is designed to reduce the systemic dosage and mitigate potential adverse reactions, including immune responses.- Flcube.com
